Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease

Annals of Oncology

Volumn 12, Issue 10, 2001, Pages 1433-1438

  Jagdev, S P ^a   Purohit, O P ^a   Heatley, S ^a   Herling, C ^b   Coleman, R E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

Bisphosphonates; Bone pain; Clodronate; Collagen crosslinks; Pamidronate

Indexed keywords

BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; COLLAGEN; PAMIDRONIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOCHEMISTRY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG EFFECT; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PAIN ASSESSMENT; PRIORITY JOURNAL; PROTEIN CROSS LINKING; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; URINALYSIS;

EID: 0035178874     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012506426440     Document Type: Article

References (28)

1. Bisphosphonates: Mechanisms of action
2. Randomised double-blind comparisons of single infusions of pamidronate or clodronate for hypercalcaemia of malignancy
3. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
4. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
5. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
6. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
7. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial
8. High-dose intravenous pamidronate for metastatic bone pain
9. A double-blind crossover trial of intravenous clodronate in patients with metastatic bone disease and pain
10. A randomised controlled trial of intravenous clodronate in patients with metastatic bone disease and pain
11. High dose pamidronate: Clinical and biochemical effects in metastatic bone disease
12. Palliation of painful bone metastases from prostate cancer using sodium etidronate: Results of a randomised, prospective, double-blind placebo-controlled study
13. Effect of daily etidronate on the osteolysis of multiple myeloma
14. A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer
15. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial
16. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
17. Clodronate decreases the frequency of skeletal metastases in women with breast cancer
18. Effect of oral clodronate on metastatic bone pain: A double-blind, placebo-controlled study
19. American Society of Clinical Oncology Guideline on the role of bisphosphonates in breast cancer
20. Continuous oral vs. intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases
21. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease
22. Markers of bone resorption in patients treated with pamidronate
23. Biochemical monitoring predicts response in bone to systemic treatment
24. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: A randomised, multicenter phase III trial
25. Use of bisphosphonates in cancer patients
26. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease
27. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma
28. Reduced morbidity from skeletal metastases in breast cancer patients during long term bisphosphonate (APD) treatment